NASDAQ:INGN - Inogen Stock Price, Forecast & News

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen Inc (NASDAQ:INGN) announced its earnings results on Tuesday, November, 5th. The medical technology company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The medical technology company earned $91.76 million during the quarter, compared to analysts' expectations of $91.65 million. Inogen had a return on equity of 9.89% and a net margin of 8.76%. Inogen's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the business posted $0.73 EPS. View Inogen's Earnings History.

Inogen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Inogen.

Inogen will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Inogen issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $361.4-362.4 million, compared to the consensus revenue estimate of $372.96 million.

7 analysts have issued 1-year target prices for Inogen's shares. Their forecasts range from $47.00 to $90.00. On average, they expect Inogen's stock price to reach $65.00 in the next year. This suggests a possible upside of 47.3% from the stock's current price. View Analyst Price Targets for Inogen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inogen.

News coverage about INGN stock has trended very negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inogen earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned news stories about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Inogen.

Some companies that are related to Inogen include Wright Medical Group (WMGI), Avanos Medical (AVNS), Establishment Labs (ESTA), RTI Surgical (RTIX), Invacare (IVC), Sientra (SIEN), Lakeland Industries (LAKE), ConforMIS (CFMS), Histogenics (HSGX), COLLPLANT HOLDI/S (CLGN), Bionik Laboratories (BNKL), NanoVibronix (NAOV), Rewalk Robotics (RWLK), Allied Healthcare Products (AHPI) and Ocugen (OCGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), First Solar (FSLR), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Dynavax Technologies (DVAX).

Inogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.44%), AQR Capital Management LLC (3.92%), State Street Corp (3.00%), New York State Common Retirement Fund (2.25%), Rockefeller Capital Management L.P. (1.28%) and Riverbridge Partners LLC (1.23%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Cubist Systematic Strategies LLC, UBS Asset Management Americas Inc., State Street Corp, Marshall Wace LLP, American International Group Inc. and AlphaCrest Capital Management LLC. View Insider Buying and Selling for Inogen.

INGN stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Point72 Asset Management L.P., Beacon Investment Advisory Services Inc., Tamarack Advisers LP, Great West Life Assurance Co. Can, Jane Street Group LLC, Pinebridge Investments L.P. and Oxford Asset Management LLP. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch and Loren L Mcfarland. View Insider Buying and Selling for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $44.13.

Inogen has a market capitalization of $970.86 million and generates $358.11 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $2.30 on an earnings per share basis. Inogen employs 1,099 workers across the globe.View Additional Information About Inogen.

The official website for Inogen is http://www.inogen.com/.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]